| ESPERION THERAPEUTICS |
| USA |
| Gesundheit |
| US29664W1053 / A1W1SJ |
| 0ET (Frankfurt) / ESPR (NASDAQ) |
| FRA:0ET, ETR:0ET, 0ET:GR, NASDAQ:ESPR |
| - |
| https://www.esperion.com/ |
|
Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLET..
>Volltext.. |
| 690.88 Mio. EUR |
| 1027.67 Mio. EUR |
| 359.76 Mio. EUR |
| 65.26 Mio. EUR |
| -6.39 Mio. EUR |
| -0.05 EUR |
| 467.77 Mio. EUR |
| 134.32 Mio. EUR |
| - |
| 0.52 |
| 50.87% |
| 95.46% |
| - |
| - |
| - |
| - |
| ESPERION |
| 19.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|